OR| Oregon’s Department of Consumer and Business Services has adopted a temporary administrative order (ID 1-2026) effective February 13 through August 11, 2026, to restore mandatory annual price-increase reporting by prescription drug manufacturers under the Prescription Drug Price Transparency Act (HB 4005) following the Ninth Circuit’s reversal of a prior district court decision that had led the state to make these reports voluntary in 2025; the order amends OAR 836-200-0515 and 836-200-0530 so that manufacturers must again submit detailed, electronically filed, machine-readable reports each March 15 for drugs costing at least $100 for a one‑month supply with net yearly price increases of 10 percent or more, including extensive pricing, cost, revenue, and justification data, ensuring alignment with ORS 646A.689 and avoiding compliance gaps or civil penalties while permanent rulemaking is pursued for 2027 and beyond.
Key Points:
- Reports must be electronically submitted and include detailed data on prices over time, costs, revenues, profits, and factors contributing to the price increase, plus any other information the manufacturer deems relevant.
- Temporary rules revert price increase reports from voluntary back to mandatory and reestablish the March 15 annual filing deadline for 2026 reports.
- Affected drugs are those with a one‑month supply price of at least $100 and a net yearly price increase of 10 percent or more in the prior calendar year.
Click here to see OR Temporary Administrative Order ID1.2026